Bank of America
APUS

Bank of America’s Apimeds Pharmaceuticals US APUS Stock Holding History

Bank of America’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$66 – 7208
2025
Q4 		$66 Buy
4
+1
+33% +$21 ﹤0.01% 6911
2025
Q3 		$52 Hold
3
– – ﹤0.01% 8000
2025
Q2 		$52 Buy
+3
New +$54 ﹤0.01% 8096

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America's APUS Position: Q1 2026 in Review

Bank of America sold out of Apimeds Pharmaceuticals US (APUS) in Q1 2026, closing a stake of 4 shares — an estimated $66 sold.

Bank of America first reported a position in APUS in Q2 2025 and held it in 3 quarters. The position peaked at $66 in Q4 2025. 6 funds tracked by Wall St. Rank hold APUS as of Q1 2026.

  • Bank of America reported no remaining Apimeds Pharmaceuticals US position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 4 Apimeds Pharmaceuticals US shares in Q1 2026, an estimated $66.
  • Bank of America first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and held it in 3 quarters.
  • Bank of America's Apimeds Pharmaceuticals US position peaked at $66 in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.